去强化放疗在荷兰原位导管癌治疗中的应用——从2008年到2022年的全国概况

IF 3.2 3区 医学 Q2 ONCOLOGY Clinical oncology Pub Date : 2024-12-17 DOI:10.1016/j.clon.2024.103740
J Evers, M J C van der Sangen, M C van Maaren, J H Maduro, L Strobbe, M J Aarts, M C W M Bloemers, J Wesseling, D H J G van den Bongard, H Struikmans, S Siesling
{"title":"去强化放疗在荷兰原位导管癌治疗中的应用——从2008年到2022年的全国概况","authors":"J Evers, M J C van der Sangen, M C van Maaren, J H Maduro, L Strobbe, M J Aarts, M C W M Bloemers, J Wesseling, D H J G van den Bongard, H Struikmans, S Siesling","doi":"10.1016/j.clon.2024.103740","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Ductal Carcinoma In Situ (DCIS) treated by breast-conserving surgery followed by radiotherapy aims to decrease the probability of locally recurrent disease. The role of whole breast irradiation, specifically in DCIS having low recurrence risk and low risk of becoming invasive, is increasingly debated. Also, the added value of applying boost irradiation in DCIS has been questioned. Hence, we evaluated the nationwide radiotherapy use in DCIS treatment in the Netherlands.</p><p><strong>Materials and methods: </strong>Women diagnosed with DCIS in 2008-2022 were identified in the Netherlands Cancer Registry. Their primary treatment was presented over time and for age groups, stratified for DCIS grade I-II and III. Factors associated with radiotherapy use after breast-conserving surgery and boost irradiation use in whole breast irradiation after breast-conserving surgery were identified.</p><p><strong>Results: </strong>In women with DCIS grade I-II (N = 16,653), the use of breast-conserving surgery without radiotherapy increased from ∼11% in 2008-2013 to ∼26% in 2017-2022. Furthermore, post-breast-conserving surgery radiotherapy increasingly concerned whole breast irradiation without a boost or partial breast irradiation. Moreover, surgery was omitted more often in recent years (30% in 2022). In DCIS grade III (N = 13,534), the use of breast-conserving surgery without radiotherapy only slightly increased in the most recent years in older patients, while boost irradiation was increasingly omitted. Whole breast irradiation and boost irradiation following breast-conserving surgery were more often applied in case of a higher risk of recurrences: young age, larger lesions, or irradical resection. Variation was observed for hospital-characteristics but not for regions.</p><p><strong>Conclusion: </strong>In DCIS, the process of omitting breast irradiation after breast-conserving surgery is clearly ongoing. Boost irradiation was administered less frequently. Furthermore, the use of partial breast irradiation was introduced in recent years. These effects are more prominent in older women and those with grade I-II DCIS.</p>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"38 ","pages":"103740"},"PeriodicalIF":3.2000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands-A Nationwide Overview From 2008 Until 2022.\",\"authors\":\"J Evers, M J C van der Sangen, M C van Maaren, J H Maduro, L Strobbe, M J Aarts, M C W M Bloemers, J Wesseling, D H J G van den Bongard, H Struikmans, S Siesling\",\"doi\":\"10.1016/j.clon.2024.103740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Ductal Carcinoma In Situ (DCIS) treated by breast-conserving surgery followed by radiotherapy aims to decrease the probability of locally recurrent disease. The role of whole breast irradiation, specifically in DCIS having low recurrence risk and low risk of becoming invasive, is increasingly debated. Also, the added value of applying boost irradiation in DCIS has been questioned. Hence, we evaluated the nationwide radiotherapy use in DCIS treatment in the Netherlands.</p><p><strong>Materials and methods: </strong>Women diagnosed with DCIS in 2008-2022 were identified in the Netherlands Cancer Registry. Their primary treatment was presented over time and for age groups, stratified for DCIS grade I-II and III. Factors associated with radiotherapy use after breast-conserving surgery and boost irradiation use in whole breast irradiation after breast-conserving surgery were identified.</p><p><strong>Results: </strong>In women with DCIS grade I-II (N = 16,653), the use of breast-conserving surgery without radiotherapy increased from ∼11% in 2008-2013 to ∼26% in 2017-2022. Furthermore, post-breast-conserving surgery radiotherapy increasingly concerned whole breast irradiation without a boost or partial breast irradiation. Moreover, surgery was omitted more often in recent years (30% in 2022). In DCIS grade III (N = 13,534), the use of breast-conserving surgery without radiotherapy only slightly increased in the most recent years in older patients, while boost irradiation was increasingly omitted. Whole breast irradiation and boost irradiation following breast-conserving surgery were more often applied in case of a higher risk of recurrences: young age, larger lesions, or irradical resection. Variation was observed for hospital-characteristics but not for regions.</p><p><strong>Conclusion: </strong>In DCIS, the process of omitting breast irradiation after breast-conserving surgery is clearly ongoing. Boost irradiation was administered less frequently. Furthermore, the use of partial breast irradiation was introduced in recent years. These effects are more prominent in older women and those with grade I-II DCIS.</p>\",\"PeriodicalId\":10403,\"journal\":{\"name\":\"Clinical oncology\",\"volume\":\"38 \",\"pages\":\"103740\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.clon.2024.103740\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clon.2024.103740","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:对导管原位癌(DCIS)行保乳手术加放疗治疗,以降低局部复发的可能性。全乳照射的作用,特别是在低复发风险和低侵袭性风险的DCIS中,越来越多的争论。此外,在DCIS中应用增强照射的附加价值也受到质疑。因此,我们评估了荷兰DCIS治疗的全国放疗使用情况。材料和方法:2008-2022年诊断为DCIS的女性在荷兰癌症登记处被确定。他们的主要治疗是根据时间和年龄组,根据DCIS分级I-II和III。确定保乳手术后放疗和保乳手术后全乳增强照射的相关因素。结果:在I-II级DCIS患者中(N = 16,653),保乳手术不放疗的使用从2008-2013年的约11%增加到2017-2022年的约26%。此外,保乳手术后的放射治疗越来越关注全乳不增强或部分乳房照射。此外,近年来,手术被省略的频率更高(2022年为30%)。在DCIS III级(N = 13,534)中,近年来在老年患者中,保乳手术不加放疗的使用仅略有增加,而增强放疗越来越少。保乳手术后的全乳照射和增强照射更常用于复发风险较高的病例:年轻、病灶较大或未根治性切除。在医院特征上观察到差异,但在地区上没有。结论:在DCIS中,保乳手术后省略乳房照射的过程显然是持续的。增强照射的使用频率较低。此外,近年来还介绍了部分乳房照射的使用。这些影响在老年妇女和I-II级DCIS患者中更为突出。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Deintensification of Radiotherapy Use in Treatment of Ductal Carcinoma In Situ in the Netherlands-A Nationwide Overview From 2008 Until 2022.

Aims: Ductal Carcinoma In Situ (DCIS) treated by breast-conserving surgery followed by radiotherapy aims to decrease the probability of locally recurrent disease. The role of whole breast irradiation, specifically in DCIS having low recurrence risk and low risk of becoming invasive, is increasingly debated. Also, the added value of applying boost irradiation in DCIS has been questioned. Hence, we evaluated the nationwide radiotherapy use in DCIS treatment in the Netherlands.

Materials and methods: Women diagnosed with DCIS in 2008-2022 were identified in the Netherlands Cancer Registry. Their primary treatment was presented over time and for age groups, stratified for DCIS grade I-II and III. Factors associated with radiotherapy use after breast-conserving surgery and boost irradiation use in whole breast irradiation after breast-conserving surgery were identified.

Results: In women with DCIS grade I-II (N = 16,653), the use of breast-conserving surgery without radiotherapy increased from ∼11% in 2008-2013 to ∼26% in 2017-2022. Furthermore, post-breast-conserving surgery radiotherapy increasingly concerned whole breast irradiation without a boost or partial breast irradiation. Moreover, surgery was omitted more often in recent years (30% in 2022). In DCIS grade III (N = 13,534), the use of breast-conserving surgery without radiotherapy only slightly increased in the most recent years in older patients, while boost irradiation was increasingly omitted. Whole breast irradiation and boost irradiation following breast-conserving surgery were more often applied in case of a higher risk of recurrences: young age, larger lesions, or irradical resection. Variation was observed for hospital-characteristics but not for regions.

Conclusion: In DCIS, the process of omitting breast irradiation after breast-conserving surgery is clearly ongoing. Boost irradiation was administered less frequently. Furthermore, the use of partial breast irradiation was introduced in recent years. These effects are more prominent in older women and those with grade I-II DCIS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical oncology
Clinical oncology 医学-肿瘤学
CiteScore
5.20
自引率
8.80%
发文量
332
审稿时长
40 days
期刊介绍: Clinical Oncology is an International cancer journal covering all aspects of the clinical management of cancer patients, reflecting a multidisciplinary approach to therapy. Papers, editorials and reviews are published on all types of malignant disease embracing, pathology, diagnosis and treatment, including radiotherapy, chemotherapy, surgery, combined modality treatment and palliative care. Research and review papers covering epidemiology, radiobiology, radiation physics, tumour biology, and immunology are also published, together with letters to the editor, case reports and book reviews.
期刊最新文献
Under-representation for Female Pelvis Cancers in Commercial Auto-segmentation Solutions and Open-source Imaging Datasets. Correspondence to the Editor: Reirradiation in Paediatric Tumors of the Central Nervous System: Outcome and Side Effects After Implementing National Guidelines. Comparing the Robustness of Intensity-modulated Proton Therapy and Proton-arc Therapy Against Interplay Effects of 4D Robust-optimised Plans for Lung Stereotactic Body Radiotherapy. OncoFlash: Research Updates in a Flash! REMIT: Reirradiation of Diffuse Midline Glioma Patients -A Nordic Society of Paediatric Haematology and Oncology Feasibility Study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1